Abstract
The endocannabinoid (EC) system is a physiological system with an important regulatory role in numerous biological functions, both centrally and peripherally. In certain conditions it can become hyperactive and induce a variety of disorders. The system has two receptor types, designated CB1 and CB2 (present respectively in the CNS and the periphery), as well as endogenous ligands (AEA and 2-AG) and equipment for transporting, synthesizing and degrading them. The discovery of specific CB1 antagonists has opened up interesting new possibilities for the treatment of obesity, diabetes and cardiometabolic risk factors.
MeSH terms
-
Animals
-
Appetite Regulation / drug effects
-
Cannabinoid Receptor Antagonists*
-
Cannabinoid Receptor Modulators / therapeutic use
-
Cannabinoids / antagonists & inhibitors*
-
Cannabinoids / pharmacology
-
Clinical Trials, Phase III as Topic
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Disease Models, Animal
-
Dyslipidemias / drug therapy
-
Humans
-
Ligands
-
Mice
-
Mice, Knockout
-
Obesity / drug therapy*
-
Piperidines / administration & dosage
-
Piperidines / pharmacology
-
Piperidines / therapeutic use*
-
Pyrazoles / administration & dosage
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Rats
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors
-
Receptor, Cannabinoid, CB2 / drug effects
-
Receptor, Cannabinoid, CB2 / physiology
-
Receptors, Cannabinoid / drug effects
-
Receptors, Cannabinoid / physiology
-
Rimonabant
-
Risk Factors
Substances
-
Cannabinoid Receptor Antagonists
-
Cannabinoid Receptor Modulators
-
Cannabinoids
-
Ligands
-
Piperidines
-
Pyrazoles
-
Receptor, Cannabinoid, CB1
-
Receptor, Cannabinoid, CB2
-
Receptors, Cannabinoid
-
Rimonabant